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ABSTRACT
Introduction: Diabetes mellitus (DM) carries an
elevated risk for cardiovascular disease. Here, we
assessed alirocumab efficacy and safety in peo-
ple with/without DM from five placebo-con-
trolled phase 3 studies.
Methods: Data from up to 78 weeks were ana-
lyzed in individuals on maximally tolerated
background statin. In three studies, alirocumab
75 mg every 2 weeks (Q2W) was increased to
150 mg Q2W at week 12 if week 8 low-density
lipoprotein cholesterol (LDL-C) was C 70 mg/
dL; two studies used alirocumab 150 mg Q2W
throughout. The primary endpoint was per-
centage change in LDL-C from baseline to week
24.
Results: In the alirocumab 150 mg pool
(n = 2416), baseline LDL-C levels were
117.4 mg/dL (DM) and 130.6 mg/dL (without
DM), and in the 75/150 mg pool (n = 1043)
112.8 mg/dL (DM) and 133.0 mg/dL (without
DM). In the 150 mg Q2W group, week 24 LDL-C
reductions from baseline were observed in per-
sons with DM (- 59.9%; placebo, - 1.4%) and
without DM (- 60.6%; placebo, ? 1.5%); 77.7%
(DM) and 76.8% (without DM) of subjects
achieved LDL-C\70 mg/dL. In the alirocumab
75/150 mg group, 26% (DM) and 36% (without
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DM) of subjects received dose increase. In this
group, week 24 LDL-C levels changed from
baseline by - 43.8% (DM; placebo, ? 0.3%) and
- 49.7% (without DM; placebo, ? 5.1%); LDL-
C\70 mg/dL was achieved by 68.3% and
65.8% of individuals, respectively. At week 24,
alirocumab was also associated with improved
levels of other lipids. Adverse event rates were
generally comparable in all groups
(79.8–82.0%).
Conclusions: Regardless of DM status, alir-
ocumab significantly reduced LDL-C levels;
safety was generally similar.
Funding: Sanofi and Regeneron Pharmaceuti-
cals, Inc.
Plain Language Summary: Plain language
summary available for this article.
Keywords: Alirocumab; Cholesterol-lowering
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PLAIN LANGUAGE SUMMARY
High cholesterol puts people at risk of heart
disease, especially those with diabetes. Physi-
cians set individualized cholesterol treatment
goals for each patient. Statins, prescribed to
reduce high cholesterol levels, may not lower
cholesterol enough in all people. Alirocumab is
a medication for lowering cholesterol levels.
Alirocumab is intended for use in combination
with maximally tolerated statin. Here we
compared the effects of alirocumab to 1054
people with diabetes to 2445 people without
diabetes.
Our study showed that most people with and
without diabetes reached the cholesterol goal of
less than 70 mg per deciliter after 24 weeks of
treatment with individualized alirocumab
doses. Treatment with alirocumab 150 mil-
ligrams every 2 weeks resulted in 78% of people
with diabetes and 77% of people without dia-
betes reaching this goal. Treatment with alir-
ocumab 75 mg every 2 weeks (with some
individuals getting their dose increased to
150 mg) also produced similar results in people
with diabetes (68%) and without diabetes
(66%). Eighty percent of people with diabetes
and 80% of people without diabetes had adverse
reactions with alirocumab treatment. Similar
rates of adverse reactions were reported in the
corresponding placebo groups with diabetes
(82%) and without diabetes (81%). Regardless of
diabetes status, the most common adverse
reactions among alirocumab-treated people
were common cold, chest infection, and injec-
tion-site reaction.
In summary, alirocumab provides an addi-
tional treatment option for people with and
without diabetes who do not to reach their
cholesterol goals, even with maximally toler-
ated statin dose.
INTRODUCTION
Cardiovascular disease (CVD) is the most
common cause of death in persons with dia-
betes mellitus (DM) [1, 2]. Individuals with DM
are, on average, at double the risk of
atherosclerotic CVD (ASCVD) in comparison to
those without DM, and the presence of dys-
lipidemia in people with type 2 DM further
increases the risk of adverse cardiovascular
outcomes [3, 4].
The elevated cardiovascular risk associated
with DM is recognized in guidelines [1, 3, 5, 6],
which recommend more intense management
strategies for low-density lipoprotein choles-
terol (LDL-C)-lowering in individuals with DM
than for the general population. Statins are
recommended as first-line therapy to reduce
LDL-C in DM [1, 5, 7, 8]. However, many people
with DM have persistent lipid abnormalities
despite statin treatment [9, 10]. The 2017
updated American College of Cardiology Expert
Consensus Task Force and the 2018 American
Diabetes Association standards of care recom-
mend that a proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitor be considered in
individuals with ASCVD and DM whose LDL-C
levels are not optimally controlled on high-in-
tensity statin therapy [6, 8].
The 2017 update of the European Society of
Cardiology/European Atherosclerosis Society
Task Force also recommends the use of a PCSK9
inhibitor for two categories of individuals with
DM, depending on LDL-C levels: (1) individuals
with DM and clinical ASCVD whose LDL-C
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levels are[ 100 mg/dL and (2) individuals with
DM and familial hypercholesterolemia without
clinical ASCVD whose LDL-C levels are
[140 mg/dL, despite maximally tolerated sta-
tin and ezetimibe therapies [11].
The lipid profile of type 2 DM is character-
ized by reduced high-density lipoprotein
cholesterol (HDL-C), high triglycerides, and an
increase in the proportion of LDL-C particles
that are small and dense, with or without high
levels of LDL-C [12, 13]. In the ODYSSEY DM-
INSULIN study (NCT02585778), alirocumab
75 mg every 2 weeks (Q2W; with possible dose
increase to 150 mg Q2W) significantly reduced
LDL-C levels and other lipids in individuals
with type 1 DM (n = 76) or type 2 DM (n = 441)
treated with insulin [14]. Furthermore, in indi-
viduals with type 2 DM and mixed dyslipi-
demia, the same alirocumab dosing regimen
also resulted in significant reductions in non-
HDL-C, LDL-C, and other lipids in ODYSSEY
DM-DYSLIPIDEMIA (NCT02642159) [15]. How-
ever, the efficacy and safety of alirocumab
75 mg Q2W (with possible dose adjustment to
150 mg Q2W) and 150 mg Q2W (without dose
adjustment) have not been compared in a larger
pool of individuals with and without DM trea-
ted for longer duration. This subgroup analysis
of five placebo-controlled phase 3 studies
(LONG TERM [NCT01507831] [16], HIGH FH
[NCT01617655] [17], COMBO I [NCT01644175]
[18], FH I [NCT01623115] [19], and FH II
[NCT01709500] [19]) aimed to compare the
efficacy and safety of alirocumab in a large
group of individuals with and without DM at
baseline, with the primary efficacy endpoint
being LDL-C reduction from baseline to
week 24.
METHODS
Trial Participants and Study Designs
The current analysis used patient-level data
from study participants according to alir-
ocumab dosing regimen who enrolled for five
double-blind, randomized, placebo-controlled
ODYSSEY phase 3 studies with 52–78 weeks’
treatment duration. Methods for each of the
individual studies have been previously repor-
ted [16–19].
In summary, all participants, with or without
DM, had hypercholesterolemia at study entry
and were on maximally tolerated, stable, back-
ground statin therapy with or without other
lipid-lowering agents. The FH I and FH II studies
recruited participants with heterozygous famil-
ial hypercholesterolemia (HeFH) and at either
very high risk (LDL-C C 70 mg/dL with prior
CVD) or high risk (LDL-C C 100 mg/dL but no
prior CVD). The HIGH FH study enrolled indi-
viduals with HeFH and LDL-C levels C 160 mg/
dL. The LONG TERM study included partici-
pants who either had HeFH or established
coronary heart disease (CHD) or CHD risk
equivalents based on the European Systematic
Coronary Risk Estimation (SCORE), with base-
line LDL-C C 70 mg/dL. The COMBO I study
included participants with either established
CVD and LDL-C C 70 mg/dL, or CHD risk
equivalents and LDL-C C 100 mg/dL, based on
the European SCORE, which included DM with
other risk factors or chronic kidney disease.
All study protocols were approved by the
appropriate institutional review boards, and all
participants provided informed, written con-
sent. All trials were performed in accordance
with the ethical principles that have their origin
in the Declaration of Helsinki and all applicable
amendments laid down by the World Medical
Assemblies and the International Conference
Harmonisation Guidelines for Good Clinical
Practice.
Participants were randomized to alirocumab
or placebo groups in a 2:1 ratio. Two studies
(LONG TERM and HIGH FH) used an alir-
ocumab dose of 150 mg Q2W throughout the
trial period. The other three studies (COMBO I,
FH I, and FH II) used an initial alirocumab dose
of 75 mg Q2W, with an increase to 150 mg
Q2W at week 12 if the LDL-C level at week 8
remained C 70 mg/dL. All doses were delivered
by subcutaneous injection (alirocumab 75 mg,
alirocumab 150 mg, or placebo) using a 1-mL
dose volume.
Participants were classified as having DM
(type 1 or 2) or not, according to medical his-
tory reported by the investigator.
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Efficacy Analysis
Efficacy was compared in individuals with and
without DM in two pools according to alir-
ocumab dose regimen (pool of 150 mg Q2W
studies; pool of 75 mg Q2W with possible
increase to 150 mg Q2W, abbreviated in the text
to 75/150 mg Q2W).
The main efficacy endpoint for this pooled
analysis was the mean percentage change in
calculated LDL-C from baseline to week 24 (the
primary endpoint of the individual studies).
Other efficacy endpoints included percentage
change in calculated LDL-C from baseline to
week 12 (prior to potential dose increase in tri-
als utilizing the 75/150 mg Q2W dosing regi-
men), proportion of individuals achieving risk-
based LDL-C goals, and the percentage change
in other lipid parameters from baseline to
weeks 12 and 24. Mean percentage change in
LDL-C and other lipid parameters over time is
also reported up to week 78.
Changes from baseline for the main LDL-C
efficacy endpoint and other lipid values were
statistically evaluated with an intention-to-treat
(ITT) approach, which included lipid data from
all randomized persons regardless of adherence
to treatment. The analysis utilized a mixed-ef-
fect model with repeated measures to account
for missing data, as previously described [20].
Data on changes over time were presented
according to ITT analysis, and on-treatment
analysis using a modified ITT approach, which
included only lipid data collected while the
individual was receiving study treatment.
Other lipid parameters were analyzed either
in the same way as the main efficacy endpoint
or, in the case of lipoprotein (a) [Lp(a)] and
triglyceride (TG) percentage changes, and LDL-
C goal achievement proportions, analysis
involved a multiple imputation approach then
robust regression (for Lp(a) and TG percentage
changes) or logistic regression (for LDL-C goal
achievement), in the ITT population.
Consistency of treatment effect across sub-
groups was assessed by providing interaction
p values. A further subgroup analysis was per-
formed to compare alirocumab efficacy in per-
sons with and without DM according to HeFH
status at week 12 and week 24.
Safety Analysis
Safety data are reported in subgroups of indi-
viduals assigned to alirocumab or placebo,
regardless of alirocumab dose, according to
baseline DM status. All adverse events, regard-
less of seriousness and irrespective of potential
relationship to alirocumab, were recorded by
the investigators up to the last visit planned in
the protocol. Treatment-emergent adverse
events (TEAEs) were defined as events that
developed, worsened, or became serious
between the first and last dose of study treat-
ment plus 70 days, classified according to the
Medical Dictionary for Regulatory Activities.
Adverse events of special interest included
injection-site reactions, general allergic events,
neurocognitive disorders, and adjudicated car-
diovascular events. Statistical analysis of the
safety population included all randomized
individuals who received at least one dose or
part of a dose of study drug, and safety data
were analyzed by descriptive statistics.
The effect of alirocumab treatment on gly-
cated hemoglobin (HbA1c) and fasting plasma
glucose (FPG) was also evaluated according to
DM status throughout the studies using
descriptive statistics conducted on the safety
population.
RESULTS
Study Participants
In total, 30.1% of alirocumab-treated individu-
als (n = 699) and 30.2% of those receiving pla-
cebo (n = 355) were classified as having DM at
baseline (n = 1625 and n = 820, respectively,
were classified as not having diabetes) (Table 1;
Supplementary Fig. 1). In total, 24 persons
(0.69%) had type 1 DM and the remainder had
type 2 DM. Individuals with DM were generally
older and had a higher BMI versus those with-
out DM. Fewer subjects with DM were male,
white, or had HeFH compared with subjects
without DM (Table 1). Fewer participants with
DM had a history of ASCVD (62.5–62.8%)
compared with those without DM
(72.4–74.6%). Regardless of DM status, all
1320 Diabetes Ther (2018) 9:1317–1334
Table 1 Baseline demographics, clinical characteristics, and lipid proﬁle in individuals with and without DM (randomized
population)
Individuals with DM (n = 1054) Individuals without DM (n = 2445)
Alirocumab
(n = 699)
Placebo
(n = 355)
Alirocumab
(n = 1625)
Placebo
(n = 820)
Age, years, mean (SD) 61.7 (9.5) 60.8 (10.2) 57.3 (12.2) 57.9 (11.7)
Male, n (%) 405 (57.9) 192 (54.1) 1010 (62.2) 520 (63.4)
Race, white, n (%) 581 (83.1) 290 (81.7) 1558 (95.9) 782 (95.4)
BMI, kg/m2, mean (SD) 32.4 (6.3) 32.9 (6.0) 29.1 (5.0) 29.2 (5.1)
ASCVDa, n (%) 439 (62.8) 222 (62.5) 1176 (72.4) 612 (74.6)
CHD, n (%) 388 (55.5) 193 (54.4) 1066 (65.6) 573 (69.9)
ACS, n (%) 247 (35.3) 134 (37.7) 733 (45.1) 394 (48.0)
Coronary revascularization
procedure, n (%)
271 (38.8) 133 (37.5) 735 (45.2) 389 (47.4)
Other clinically signiﬁcant
CHDb, n (%)
145 (20.7) 74 (20.8) 477 (29.4) 248 (30.2)
Peripheral arterial disease, n (%) 32 (4.6) 23 (6.5) 65 (4.0) 33 (4.0)
Ischemic stroke, n (%) 60 (8.6) 26 (7.3) 139 (8.6) 60 (7.3)
HeFH, n (%) 85 (12.2) 55 (15.5) 753 (46.3) 364 (44.4)
High-intensity statinc, n (%) 311 (44.5) 153 (43.1) 1016 (62.5) 529 (64.5)
With HeFH 63 (74.1) 42 (76.4) 600 (79.7) 294 (80.8)
Without HeFH 248 (40.4) 111 (37.0) 416 (47.7) 235 (51.5)
With ASCVD 213 (48.5) 115 (51.8) 697 (59.3) 377 (61.6)
Without ASCVD 98 (37.7) 38 (28.6) 319 (71.0) 152 (73.1)
Baseline lipids, mean (SD), mg/dL
Calculated LDL-C 116.5 (37.6) 119.7 (41.2) 131.3 (48.9) 129.8 (45.9)
Non-HDL-C 150.0 (42.6) 151.6 (46.7) 158.1 (52.1) 157.2 (49.2)
Apo B 101.6 (26.4) 101.1 (28.0) 105.4 (30.0) 105.2 (28.7)
Lp(a), median (Q1, Q3) 21.1 (6.0, 58.0) 19.0 (5.8, 61.6) 26.0 (10.0, 73.0) 24.9 (7.5, 71.8)
Fasting TGs, median (Q1, Q3) 147.0 (108.0, 205.3) 144.0 (105.3, 205.0) 118.0 (85.0, 163.7) 120.7 (88.0, 169.0)
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patients received statin therapy. Baseline high-
intensity statin use was lower among individu-
als with DM (43.1–44.5%) versus without DM
(62.5–64.5%), but was greater in individuals
with HeFH versus those without (74.1–80.8% vs
37.0–51.5%, respectively). In total, 48.6–61.6%
of individuals with ASCVD and 28.6–73.1% of
those without ASCVD received high-intensity
statin at baseline (Table 1).
Overall, individuals with DM had lower
baseline Lp(a) and HDL-C levels but higher TG
levels than individuals without DM (Table 1).
Among individuals with DM, 27.8% were
receiving injectable treatments which always
consisted of insulin (27.8%), sometimes com-
bined with a glucagon-like peptide 1 antagonist
(GLP 1; 3.3%). No individuals were receiving
GLP 1 antagonist only.
Efficacy
LDL-C Outcomes: Pool of Alirocumab 150 mg
Q2W Studies (LONG TERM and HIGH FH)
At week 24 in the full alirocumab 150 mg Q2W
cohort, the least-squares mean LDL-C levels
were changed from baseline by - 59.9% (with
DM; placebo, - 1.4%) and - 60.6% (without
DM; placebo, ? 1.5%) (Table 2). Regardless of
high-intensity statin status, the LDL-C per-
centage change from baseline to week 24 was
similar in participants with and without DM
(Fig. 1). Mean week 24 LDL-C levels of 52.3 mg/
dL were achieved in alirocumab-treated indi-
viduals with DM (absolute change from base-
line, - 73.6 mg/dL) and 50.2 mg/dL in those
without DM (absolute change from baseline,
- 75.7 mg/dL). LDL-C levels\ 70 mg/dL at
week 24 were attained by 77.7% of alirocumab-
treated individuals with DM and 76.8% of those
without DM (placebo, 10.3% and 6.4%, respec-
tively) (Table 2).
In the same alirocumab 150 mg Q2W group,
least-squares mean percentage change from
baseline to week 12 in LDL-C levels was
- 62.1% in individuals with DM (placebo,
? 0.1%) and - 62.9% in individuals without
DM (placebo, ? 1.7%) (Supplementary Table 1).
At week 12, alirocumab-associated LDL-C
changes were similar for patients with or with-
out DM in the HeFH subgroup (DM, - 56.2%;
non-DM, - 57.2%) and the non-HeFH subgroup
(DM, - 62.5%; non-DM, - 65.4%) (Supple-
mentary Tables 2 and 3). LDL-C levels were
maintained through 78 weeks in individuals
with and without DM in the on-treatment
population (Fig. 2a). The reductions up to
78 weeks for the ITT population are presented in
Supplementary Fig. 2A.
In the HeFH subjects from the LONG TERM
and HIGH FH studies, least-squares mean LDL-C
levels changed from baseline to week 24 by
Table 1 continued
Individuals with DM (n = 1054) Individuals without DM (n = 2445)
Alirocumab
(n = 699)
Placebo
(n = 355)
Alirocumab
(n = 1625)
Placebo
(n = 820)
HDL-C 47.6 (11.6) 48.1 (12.3) 51.1 (13.8) 50.5 (13.2)
ACS acute coronary syndrome, Apo apolipoprotein, ASCVD atherosclerotic cardiovascular disease, BMI body mass index,
CHD coronary heart disease, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, HeFH heterozygous
familial hypercholesterolemia, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), Q1, Q3 ﬁrst and third
quartiles, SD standard deviation, TG triglyceride
a Included CHD, peripheral arterial disease, and ischemic stroke; for study FH II, ischemic stroke, transient ischemic attack,
carotid endarterectomy, or carotid artery stent procedure and renal artery stent procedure were also included
b Diagnosed by invasive or non-invasive testing
c High-intensity statins deﬁned as atorvastatin 40–80 mg, rosuvastatin 20–40 mg, or simvastatin 80 mg
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- 53.1% (with DM; placebo, ? 0.1%) and
- 55.3% (without DM; placebo, ? 1.5%) (Sup-
plementary Table 4). In subjects without HeFH,
the least-squares mean LDL-C changes from
baseline to week 24 were - 60.3% in subjects
with DM (placebo, - 1.4%) and - 62.9% in
those without DM (placebo, ? 1.6%) (Supple-
mentary Table 5).
LDL-C Outcomes: Pool of Alirocumab
75/150 mg Q2W Studies (FH I, FH II,
and COMBO I)
At week 24 in the full 75/150 mg Q2W cohort,
least-squares mean percentage change from
baseline in LDL-C level was - 43.8% (with DM;
placebo, ? 0.3%) and - 49.7% (without DM;
placebo, ? 5.1%) (Table 2). Mean week 24 LDL-
C levels of 71.1 mg/dL were achieved in alir-
ocumab-treated individuals with DM (absolute
change from baseline, - 58.3 mg/dL) and
63.1 mg/dL in those without DM (absolute
change from baseline, - 66.3 mg/dL). Subgroup
analysis with and without high-intensity statin
demonstrated similar LDL-C reductions at
week 24, regardless of DM status (Fig. 1).
At week 12 in this cohort (i.e., before possi-
ble dose increase), least-squares mean percent-
age change from baseline to week 12 in LDL-C
levels was - 38.0% in persons with DM
(placebo, ? 7.0%) and - 46.0% in those with-
out DM (placebo, ? 3.4%) in the alirocumab
75/150 mg Q2W treatment pool (Supplemen-
tary Table 1). When the HeFH and non-HeFH
subjects in this cohort were examined sepa-
rately, similar percentage reductions from
baseline to week 12 were observed in alir-
ocumab-treated groups, except for a less pro-
nounced change in LDL-C levels in individuals
with DM in the HeFH subgroup (- 34.9%; pla-
cebo, ? 3.6%) (Supplementary Tables 2 and 3).
The protocol for the three studies starting
with the alirocumab 75 mg Q2W dose specified
a blinded dose increase from 75 mg to 150 mg
Q2W at week 12 (if week 8 LDL-C levels were
C 70 mg/dL); 26.2% of individuals with DM
received a dose increase to 150 mg Q2W, as did
36.4% of those without DM. In subjects
remaining on 75 mg Q2W, the baseline LDL-C
levels were lower in those with DM (99.5 mg/
dL) versus subjects without DM (117.9 mg/dL;
interaction p value\ 0.0001). In subjects
receiving alirocumab dose increase to 150 mg
Q2W, the baseline LDL-C levels were 149.7 mg/
dL (DM) and 159.4 mg/dL (without DM).
LDL-C reductions were maintained with
alirocumab 75/150 mg Q2W until end of study
treatment, regardless of DM status, in the on-
treatment population (Fig. 2a). Similar LDL-C
Fig. 1 Percentage change from baseline in calculated
LDL-C at week 24—subgroup analysis by DM status
and statin intensity at baseline (intention-to-treat popu-
lation). High-intensity statin deﬁned as atorvastatin
40–80 mg, rosuvastatin 20–40 mg, or simvastatin 80 mg.
CI conﬁdence interval, DM diabetes mellitus, LDL-C low-
density lipoprotein cholesterol, LS least-squares, SE stan-
dard error
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reductions were observed in the ITT population
(Supplementary Fig. 2a).
At week 24, LDL-C\70 mg/dL was attained
by 68.3% of individuals in the alirocumab
group with DM and 65.8% without DM (pla-
cebo, 5.9% and 2.8%, respectively) (Table 2).
In the HeFH subgroup, the proportion of
individuals requiring dose increase from alir-
ocumab 75 mg to 150 mg Q2W was 48.7% (DM)
and 41.2% (without DM). At week 24, least-
squares mean percentage changes in LDL-C
level were - 52.3% in persons with DM
(placebo, ? 2.7%) and - 48.4% in those with-
out DM (placebo, ? 7.6%) (Supplementary
Table 4). In the non-HeFH subgroup, 16.5% of
persons with DM and 17.0% of those without
DM received dose adjustment at week 12. In
this same group, the week 24 least-squares mean
LDL-C levels changed from baseline by - 42.2%
in persons with DM (placebo, - 2.6%) and
- 53.2% in those without DM in the subgroup
(placebo, - 2.0%) (Supplementary Table 5).
Other Lipid Parameters
From baseline to week 24, alirocumab treatment
was associated with reduced levels of
apolipoprotein (Apo) B, Lp(a), non-HDL-C, and
TGs, and increased levels of HDL-C (Table 2). In
the alirocumab 150 mg Q2W pool, no differ-
ences between subjects with and without DM
were observed (Table 2). In the alirocumab
75/150 mg Q2W pool, lower percentage chan-
ges in Apo B and non-HDL-C were observed in
participants with DM versus those without (in-
teraction P values\0.05) (Table 2). The
bFig. 2 Percentage change from baseline over time for
a LDL-C, b Apo B, c Lp(a), d non-HDL-C, e TGs, and
f HDL-C according to DM status for the alirocumab
150 mg Q2W and 75/150 mg Q2W treatment pools
(modiﬁed intention-to-treat population). Apo apolipopro-
tein, DM diabetes mellitus, HDL-C high-density lipopro-
tein cholesterol, LDL-C low-density lipoprotein
cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W
every 2 weeks, SE standard error, TG triglyceride
Fig. 2 continued
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percentage changes in TG and HDL-C levels
were similar regardless of DM status.
From baseline to week 12, alirocumab dosing
regimens of 150 mg Q2W and 75/150 mg Q2W
were associated with improved levels of Apo B,
Lp(a), non-HDL-C, TGs, and HDL-C in subjects
with or without DM (Supplementary Table 1).
In persons with and without HeFH, similar
alirocumab efficacy was observed at week 12,
regardless of DM status and alirocumab dosing
regimen, except for lower Apo B and non-HDL-
C levels in individuals with HeFH in the alir-
ocumab 75/150 mg group with DM (interaction
p value\0.05 between persons with DM and
those without) (Supplementary Tables 2 and 3).
Reduced levels of other lipids were observed
from week 4 and maintained for up to 78 weeks
in individuals with and without DM in the on-
treatment population (Fig. 2b–f). The lipid
levels for the ITT population were similar
(Supplementary Fig. 2B–F). In the HeFH group,
improvements in other lipids from baseline to
week 24 were seen in individuals with DM and
without, regardless of alirocumab dosing (Sup-
plementary Table 4). No differences between
subjects with and without DM were observed in
the non-HeFH group either, except for lower
mean percentage reductions in Apo B levels in
subjects with DM in both alirocumab groups
and lower mean percentage reductions in non-
HDL-C levels in subjects with DM in the alir-
ocumab 150 mg Q2W pool (interaction
p value\0.05 between persons with DM and
those without; Supplementary Table 5).
No correlation was found between baseline
HbA1c levels and LDL-C reductions in alir-
ocumab-treated individuals with DM at week 24
(Supplementary Fig. 3).
Safety Analysis
Overall, the incidence of TEAEs was similar
between groups, occurring in 79.9% with DM
and 79.8% without DM in alirocumab-treated
individuals versus 82.0% and 81.0% in the pla-
cebo groups, respectively (Table 3). The most
common TEAEs occurring in C 5% of individ-
uals treated with alirocumab were nasopharyn-
gitis, reported in 11.5% (n = 80) of individuals
with DM and 13.0% (n = 211) of those without
DM, and upper respiratory tract infection,
reported in 7.9% (n = 55) and 6.6% (n = 107),
respectively. Among alirocumab-treated indi-
viduals, 3.7% (n = 26) of those with DM and
8.7% (n = 141) of individuals without DM
reported injection-site reactions (Table 3).
Overall, 20.3% (alirocumab) and 23.9% (pla-
cebo) of subjects in the DM group and 15.0%
(alirocumab) and 14.3% (placebo) of those
without DM experienced treatment-emergent
serious adverse events. Discontinuation rates
were 5.6% (alirocumab) and 8.0% (placebo) in
individuals with DM, and 5.4% (alirocumab)
and 5.7% (placebo) in those without DM
(Table 3). Occurrence of adverse events of spe-
cial interest in alirocumab-treated individuals
was generally similar regardless of DM status
(Table 3). Overall, the median exposure to ran-
domized treatment was 78 weeks in both the
alirocumab and control groups, regardless of
DM status. Mean HbA1c and FPG levels
remained unchanged in both groups through-
out the treatment period regardless of DM status
(Supplementary Table 6).
DISCUSSION
Across all studies in the ODYSSEY program,
individuals with hypercholesterolemia experi-
enced significant LDL-C reductions from base-
line compared with either placebo or ezetimibe
following alirocumab treatment with back-
ground statin therapy (± other lipid-lowering
therapies) [16–19]. Similar reductions were seen
with alirocumab treatment in individuals with
or without DM, and were maintained for up to
78 weeks.
In the present analysis, alirocumab 150 mg
Q2W resulted in 58.5% and 62.1% reductions in
LDL-C levels versus placebo at week 24 with no
significant difference being observed between
those with and those without DM, respectively.
Furthermore, LDL-C levels of\ 70 mg/dL were
achieved by the majority of persons receiving
this dose regardless of DM status (76.9–77.7%),
with mean achieved LDL-C levels of
50.2–52.3 mg/dL, regardless of DM status.
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In the pool of studies where per-protocol
dose increase from 75 mg to 150 mg Q2W
occurred if LDL-C goals were not reached at
week 8, the week 24 LDL-C levels from baseline
were changed by - 43.8% (individuals with
DM) and - 49.7% (individuals without DM) in
the alirocumab groups (placebo, ? 0.3% and
? 5.1%, respectively), with these changes being
Table 3 Adverse events in persons with and without DM (safety population)
n (%) DM (n = 1051) No DM (n = 2441)
Alirocumab
(n = 696)
Placebo
(n = 355)
Alirocumab
(n = 1622)
Placebo
(n = 819)
TEAEs 556 (79.9) 291 (82.0) 1295 (79.8) 663 (81.0)
Treatment-emergent SAEs 141 (20.3) 85 (23.9) 244 (15.0) 117 (14.3)
TEAEs leading to
discontinuation
56 (8.0) 20 (5.6) 88 (5.4) 47 (5.7)
TEAEs leading to death 7 (1.0) 5 (1.4) 9 (0.6) 8 (1.0)
Adverse events of special interest
HLT: injection site reactions 26 (3.7) 10 (2.8) 141 (8.7) 52 (6.3)
General allergic TEAE
(CMQ)
63 (9.1) 28 (7.9) 163 (10.0) 77 (9.4)
Neurocognitive disorders 9 (1.3) 6 (1.7) 12 (0.7) 3 (0.4)
Adjudicated cardiovascular
events
37 (5.3) 27 (7.6) 57 (3.5) 19 (2.3)
ALT[ 3 9 ULN, n/N (%) 11/689 (1.6) 14/349 (4.0) 34/1610 (2.1) 7/815 (0.9)
TEAEs occurring in C 5% of persons
Nasopharyngitis 80 (11.5) 35 (9.9) 211 (13.0) 107 (13.1)
Upper respiratory infection 55 (7.9) 36 (10.1) 107 (6.6) 58 (7.1)
Injection-site reaction 26 (3.7) 10 (2.8) 141 (8.7) 52 (6.3)
Bronchitis 33 (4.7) 27 (7.6) 79 (4.9) 31 (3.8)
Urinary tract infection 49 (7.0) 26 (7.3) 79 (4.9) 39 (4.8)
Arthralgia 27 (3.9) 26 (7.3) 91 (5.6) 50 (6.1)
Inﬂuenza 39 (5.6) 19 (5.4) 108 (6.7) 44 (5.4)
Back pain 33 (4.7) 17 (4.8) 90 (5.5) 53 (6.5)
Headache 29 (4.2) 16 (4.5) 90 (5.5) 48 (5.9)
Diarrhea 33 (4.7) 17 (4.8) 90 (5.5) 40 (4.9)
Myalgia 21 (3.0) 11 (3.1) 90 (5.5) 35 (4.3)
ALT alanine aminotransferase, CMQ custom MedDRA query, DM diabetes mellitus, HLT high-level term, MedDRA
Medical Dictionary of Regulatory Activities, SAE serious adverse event, TEAE treatment-emergent adverse event, ULN
upper limit of normal
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consistent regardless of DM status. Possibly as a
result of the higher LDL-C levels at baseline,
alirocumab dose was increased at week 12 in a
higher proportion of subjects without DM,
which was associated with a greater magnitude
of LDL-C reduction at week 24 in that group
(absolute LDL-C change, - 66.3 mg/dL) versus
the DM group (absolute LDL-C change,
- 58.3 mg/dL); however, similar LDL-C levels
(63.1–71.1 mg/dL) were achieved in both
groups. In the subgroup without HeFH, the
percentage of individuals requiring dose
increase was similar regardless of DM status.
Therefore, this analysis indicates that the higher
proportion of individuals in the subgroup
without DM who received alirocumab dose
increase versus the subgroup with DM could be
explained by more individuals with HeFH with
higher baseline LDL-C being included in the
subgroup without DM.
At baseline, the differences in prevalence of
HeFH, ASCVD, and high-intensity statin use,
and baseline LDL-C levels between individuals
with and without DM may reflect discrepancies
in selection criteria between the studies inclu-
ded in the analysis. Furthermore, consistent
with previous studies [21, 22], fewer individuals
with HeFH had DM (12.2–15.5%) compared
with those without HeFH (44.4–46.3%). Possi-
bly as a result of this imbalance, fewer individ-
uals in the cohort with DM had a history of
ASCVD and received high-intensity statin
compared with the cohort without DM. The
lower rate of high-intensity statin use in indi-
viduals with DM indicates that this high-risk
population is undertreated.
Overall, alirocumab treatment was generally
well tolerated with no particular differences
observed in incidence of TEAEs, serious adverse
effects, or deaths compared with placebo in
individuals with or without DM. Overall, mean
exposure to randomized treatment was similar
(78 weeks) in individuals with or without DM
regardless of treatment status. This analysis does
not allow for conclusive safety observations to
be made, in particular for rare adverse events
such as adjudicated cardiovascular events. As a
consequence, safety results should be consid-
ered in the context of the overall ODYSSEY
program.
Fewer injection-site reactions were reported
in individuals with DM, a difference that may in
part be due to a greater familiarity and tolerance
associated with glucometer and/or
injectable medication use in the DM population
(27.8% and 72.2% of persons with DM were
receiving antihyperglycemic injectable and
non-injectable medication at baseline, respec-
tively). However, as previously reported,
administration by injection does not deter per-
sons from self-administration of alirocumab
[23]. The ODYSSEY OUTCOMES study
(NCT01663402) will help to further establish if
DM status has an influence on the frequency of
injection-site reactions [24].
Mean HbA1c and FPG measurements in
individuals with DM were comparable between
alirocumab and placebo for up to 78 weeks of
treatment. These variables were comparable
between alirocumab and placebo in individuals
without DM, as previously reported [25]. On the
basis of these results, alirocumab treatment does
not appear to affect blood glucose, which is very
reassuring given that statins modestly raise the
risk of DM [26], and recent genetic publications
have suggested that the PCSK9 pathway might
be relevant to glycemia levels [27, 28]. In a
subgroup analysis of 11,031 individuals with
DM in FOURIER (median follow-up, 2.2 years),
neither HbA1c nor incidence of DM was
increased in the evolocumab groups versus the
placebo groups [29]. In contrast, a recent meta-
analysis of phase 2/3 randomized PCSK9 inhi-
bitor clinical studies (excluding FOURIER) sug-
gested that PCSK9-mediated lowering of LDL-C
does increase risk for DM [30]. Taking all of
these publications into consideration, it is not
yet clear whether LDL-C reduction per se or the
means of attaining lower LDL-C levels influence
DM risk. In the ODYSSEY and FOURIER studies,
most individuals received statin therapy, which
may mask the glycemic effect of PCSK9 inhibi-
tors [29, 31]. The results of ODYSSEY OUT-
COMES will provide key additional data
relevant to this important issue.
Overall efficacy and safety findings from
these placebo-controlled studies were consistent
with findings from studies comparing alir-
ocumab with ezetimibe and employing back-
ground statin therapy [32, 33]. A recently
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published study of the efficacy and safety of
alirocumab in individuals with type 2 DM and
mixed dyslipidemia (defined as non-HDL-
C C 100 mg/dL; TGs C 150 mg/dL and
\500 mg/dL) showed similar responses for
non-HDL-C (37.7% reduction) and TGs (13.0%
reduction) at week 24 compared to the larger
group of individuals with type 1 and 2 DM in
the present analysis [15]. In the DM-INSULIN
phase 3b study, alirocumab demonstrated simi-
lar results in reducing LDL-C and other lipids in
insulin-treated type 1 DM and type 2 DM indi-
viduals [14]; all individuals were at high car-
diovascular risk and received maximally
tolerated statin therapy.
This analysis was limited by the non-ran-
domized nature of DM status in subgroups,
which could introduce bias to the analyses.
Nevertheless, this placebo-controlled analysis of
up to 78 weeks adds to the body of evidence on
PCSK9 inhibitor use in people with DM [34].
CONCLUSION
On the basis of these data from placebo-con-
trolled phase 3 studies, DM status does not
appear to meaningfully affect lipid-modifying
efficacy or safety of alirocumab treatment, nor
does alirocumab appear to significantly affect
blood glucose control in individuals with or
without DM. The results presented here provide
support for the recent recommendation by the
American Diabetes Association that PCSK9
inhibitor therapy may be considered for indi-
viduals with DM and ASCVD [8]. The ODYSSEY
OUTCOMES study is expected to provide an
opportunity to evaluate the effect of alirocumab
in a larger sample of individuals with DM [24].
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